Charles Schwab
IMPL

Charles Schwab’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Charles Schwab’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,355
Closed -$92K – 3681
2022
Q1 		$92K Buy
14,355
+71
+0.5% +$537 ﹤0.01% 3431
2021
Q4 		$124K Hold
14,284
– – ﹤0.01% 3417
2021
Q3 		$174K Buy
14,284
+2,871
+25% +$41.7K ﹤0.01% 3342
2021
Q2 		$102K Buy
+11,413
New +$136K ﹤0.01% 3291

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Charles Schwab's IMPL Position: Q2 2022 in Review

Charles Schwab sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q2 2022, closing a stake of 14,355 shares — an estimated $92K sold.

Charles Schwab first reported a position in IMPL in Q2 2021 and held it in 4 quarters. The position peaked at $174K in Q3 2021. 36 funds tracked by Wall St. Rank hold IMPL as of Q2 2022.

  • Charles Schwab reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Charles Schwab sold 14,355 Impel Pharmaceuticals Inc. Common Stock shares in Q2 2022, an estimated $92K.
  • Charles Schwab first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Charles Schwab's Impel Pharmaceuticals Inc. Common Stock position peaked at $174K in Q3 2021.
  • 36 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.